original ) (raw )Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories
Estrella Carrillo
Clinical lymphoma, myeloma & leukemia, 2013
View PDFchevron_right
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes
Vu Duong
Annals of hematology, 2017
View PDFchevron_right
Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts
Carlos Soto
Annals of hematology, 2014
View PDFchevron_right
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification
Bruce Woda
Modern Pathology, 2008
View PDFchevron_right
Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in Myelodysplastic Syndromes and Permits a Better Definition of the Intermediate Risk Category of the Revised International Prognostic Scoring System (IPSS-R)
Elisa Luño
American journal of hematology, 2017
View PDFchevron_right
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia
Amelia Langston
Cancer, 2012
View PDFchevron_right
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes
Elisa Luño
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
View PDFchevron_right
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study
Federico Campigotto
American journal of hematology, 2014
View PDFchevron_right
Bone marrow morphology and classification systems in myelodysplastic syndromes
Aristoteles Giagounidis
Cancer Treatment Reviews, 2007
View PDFchevron_right
Early Peripheral Blood Blast Clearance during Induction Chemotherapy for Acute Myeloid Leukemia (AML) Predicts Superior Relapse-Free Survival
Louis Letendre
Blood, 2007
View PDFchevron_right
Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms
Phuong Nguyen
American journal of clinical pathology, 2014
View PDFchevron_right
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts
Aristoteles Giagounidis
Leukemia Research, 2013
View PDFchevron_right
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival
Louis Letendre
Blood, 2007
View PDFchevron_right
Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome
Jean Goasguen
Leukemia Research, 1991
View PDFchevron_right
Myeloblastic and lymphoblastic markers in acute undifferentiated leukemia and chronic myelogenous leukemia in blast crisis
Robert Taub
Cancer research, 1980
View PDFchevron_right
A retrospective evaluation of patients with myelodysplastic syndrome
Taner Kaya
Experimental Biomedical Research, 2019
View PDFchevron_right
P-065 Developing a flow cytometric maturation/differentiation index of the bone marrow for the diagnosis of myelodysplastic syndromes (MDS)
A. Symeonidis
Leukemia Research, 2013
View PDFchevron_right
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia
Tobias Klausen
Cytometry Part B: Clinical Cytometry, 2012
View PDFchevron_right
The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis
Cerasela Jardan
Romanian Review of Laboratory Medicine, 2013
View PDFchevron_right
Standards and impact of hematopathology in myelodysplastic syndromes (MDS)
Judit Csomor
Oncotarget, 2010
View PDFchevron_right
The grade of neoangiogenesis and the bone marrow blast count predict leukemic transformation-free survival in myelodysplastic syndromes
Smaranda Demian
Revista Romana de Medicina de Laborator, 2016
View PDFchevron_right
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study
Nobuhiko Emi
Leukemia Research, 2012
View PDFchevron_right
Prognostic factors of myelodysplastic syndromes—A simplified 3-D scoring system
Richard Garand
Leukemia Research, 1990
View PDFchevron_right
Therapy-Related Myelodysplastic Syndrome: Morphologic Subclassification May Not Be Clinically Relevant
Zeba Singh , R. Larson
American Journal of Clinical Pathology, 2007
View PDFchevron_right
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells
Susanne Schnittger
Haematologica, 2011
View PDFchevron_right
Myelodysplastic syndrome or acute myeloid leukemia? A study of 28 cases presenting with borderline features
Jean-paul Vernant
Cancer, 1985
View PDFchevron_right
Influence of Prognostic Factors on Overall Survival in Myelodysplastic Syndromes
Trajan Balkanov
Materia Socio Medica, 2014
View PDFchevron_right
Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance
Maryam Pourabdollah
Blood, 2017
View PDFchevron_right
A Rare Case of Acute Myeloblastic Leukemia With Blast Count Less Than 20% in Bone Marrow
alireza moafi
Case Reports in Clinical Practice, 2019
View PDFchevron_right
Evaluating the prognosis of patients with myelodysplastic syndromes
Aristoteles Giagounidis
Annals of Hematology, 2002
View PDFchevron_right
An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups
TZU HUA CHEN LIANG
International journal of laboratory hematology, 2018
View PDFchevron_right
Myelodysplastic syndrome is not merely "preleukemia
Y. Shen , Maher Albitar
Blood, 2002
View PDFchevron_right